Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PediLact
- Development stage
- Phase 3
- Lead developer
- Hormozgan University of Medical Sciences
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
PediLact is a multi-strain probiotic drop formulation containing a combination of *Lactobacillus reuteri*, *Lactobacillus rhamnosus*, and *Bifidobacterium infantis*. It is being evaluated as an adjunctive therapy to routine phototherapy for the treatment of neonatal hyperbilirubinemia (jaundice). The therapeutic rationale for using PediLact in this population is based on its ability to modulate the neonatal intestinal microbiota, which can reduce the enterohepatic circulation of bilirubin. Specifically, these probiotic strains are thought to increase intestinal motility and potentially inhibit the activity of the enzyme beta-glucuronidase, which deconjugates bilirubin in the gut and facilitates its reabsorption into the systemic circulation. Clinical research, including Phase 3 trials conducted by the Hormozgan University of Medical Sciences, has investigated the efficacy of PediLact in lowering total serum bilirubin levels and reducing the duration of phototherapy and hospital stays in both term and preterm neonates.
- Brand names
- PediLact
- Other names
- Pedilact
02
Targets
GUSB (Beta-glucuronidase)
Beyond the preview
Go deeper on PediLact.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PediLact.